We can already edit genes in human embryos. We can even do it in a way to pass the edits down generations, fundamentally changing a familys genetic makeup.
Doing it well, however, is far more difficult.
Its impossible to talk about human germline genome editing without bringing up the CRISPR baby fiasco. Over a year ago, a rogue Chinese scientist performed an edit on fertilized human embryos that, in theory, makes them resistant to HIV infection. Two twin girls were born, and both had multiple unplanned edits in their genome with unknown health consequencesconsequences that may be passed on to their offspring.
The brash attempt at making scientific history clearly shows that, ethics and morality issues aside, when it comes to germline editingthat is, performing gene edits in egg, sperm, or the embryowere simply technologically not there. Make no mistake: CRISPR may one day wipe out devastating genetic diseases throughout entire family lines, or even the human race. But to harness its power responsibly, there are plenty of technical challenges we need to master first.
This week, Rebecca Lea and Dr. Kathy Niakan at the Human Embryo and Stem Cell Laboratory at the Francis Crick Institute in London, UK, laid out those challenges in a sweeping articlein Nature. CRISPR as a gene editor is getting more specific and efficient by the day, they explained. However, for it to gradually move into germline editing, we also need to understand how the tool tangos with cells during early human development.
The data, they argue, will not only let us zoom into the creation of human life. It will also help inform the debate about potential safe and effective clinical uses of this technology, and truly unlock the doors to the human genome for good.
Correcting dangerous genetic mutations is one reason to pursue germline editing, but CRISPRing human embryos can also unveil insights into the very first stages of human embryo development. Research shows that trying to understand how human embryos form by studying mice might not be the best route, especially when it comes to using those results to tackle infertility and other medical problems. With CRISPR, we have insight into these early stages that were previously completely unattainable. We might only solve infertility issues, but perhaps also allow same-sex couples to have genetic children in the future.
Another argument is that couples already screen for life-threatening mutations during IVF, and using CRISPR on top of that is unnecessary. Not true, the authors argued. When both parents carry a similar mutation that robs them of the ability to have a healthy child, CRISPRnot selection during IVFis the answer. Ultimately, providing more options for patients empowers them to make the choice that is best for their family and circumstances, they said.
This is where it gets complicated.
The big one: were still trying to tease out how CRISPR works in cells that form the embryo, in hopes that we can cut down on potential mistakes.
Let me explain: all cells in the body have a cell cycle, somewhat analogous to a persons life cycle. Many checkpoint life events happen along the way. The cell could decide to divide and have kids, so to speak, or temporarily halt its cycle and stop its own aging. During a cycle, the cells DNA dramatically changes in number and packaging in preparation for its next stage in life.
The problem? The way CRISPR works heavily depends on the cell cycle. Although dubbed an editor, CRISPR actually vandalizes the genome, creating breaks in the DNA strands. What we call gene editing is the cells DNA repair system kicking into high gear, trying to patch up the mess CRISPR left behind. Adult cells that cant be repaired stop their own life cycle at a checkpoint for the greater good. In embryos, however, cells arent nearly as altruistic. Their checkpoints arent fully developed, so they might continue to develop even with severe mutations. Zooming back to the full picture, it means that the resulting early-stage embryo may keep accumulating damage, until it fails in the mothers womb.
To get around this, scientists have tried other ways to push an embryo into accepting a healthy DNA template after a CRISPR snip, which in theory would cut down on unwanted mutations. One idea is injecting the CRISPR machinery at a specific time into fertilized eggs, so it catches the early-stage embryo at just the right time to reduce DNA breaks in both strands. While theoretically possible, the process is kind of like a person trying to jump from a high-speed train into a specific cabin on a rapidly rotating Ferris wheel while blindfolded.
But science is making progress. Although we dont have a detailed movie of cell cycles in human embryos yet, multiple labs are beginning to piece one together, with hopes itll eventually help take off the blindfold when injecting CRISPR. Others are looking into adding CRISPR to sperm before fertilization as an alternative.
At the same time, scientists are also trying to characterize the entire scope of mutations caused by CRISPR. Its not just adding, swapping, or deleting specific letters in genes. Rather, the range of mutations is more complex, including large swaths of genetic rearrangements, unintended cuts relatively far from targeted spots, and other dramatic DNA lesions following CRISPR action. Its perhaps not surprising that the edits in CRISPR babies didnt work as intended.
Base editors, which swap one genetic letter for another, might be a better approach compared to the classic hack-and-paste, the authors said. So far, however, the tools havent yet been validated in embryosnot even those from mice.
Finally, for the edit to make a difference to the child, the embryo has to develop normally inside a womb into a baby. But success rates for assisted reproductive technologies are already fairly low. Add in a dose of genetic editing tool that cuts into an already-sensitive genomic landscape, and it becomes incredibly hard to maintain the health of the edited embryo.
Putting it all together, there is simply not enough data at present to understand the capability of early[embryos] to repair DNA, the authors said.
Far from it. Although theres much we dont yet understand, we do have an impressive range of tools to predict and evaluate mutations in human embryos. Exactly how to determine whether a gene-edited embryo is healthy remains up for debatefor example, is five unexpected mutations considered ok? What about 500 or 5,000?
That said, just having tools to diagnose the genetic health of an embryo from a tiny bit of DNA is already extremely useful, especially if we as a society decide to move into germline editing as a treatment.
With machine learning making an ever-larger splash in computational biology, these predictive tools will only become more accurate. Add to that ever-more-effective CRISPR variations, and were on the right trackas long as any potential applications of embryo editing only come after in-depth public and policy discussions and fit a number of strict ethical and safety criteria, the authors said.
In response to the CRISPR baby scandal, multiple governments and the World Health Organization have all drafted new guidelines or legislation to tap on the brakes. The technology isnt mature enough for clinical use, the authors said, and much more work is needednot just to further improve CRISPR tools, but especially for understanding how it works in human embryos.
Ultimately, were talking about potentially engineering the future of the human race. Tiptoeing, rather than stumbling ahead, is the least we can do. One must ensure that the outcome will be the birth of healthy, disease-free children, without any potential long-term complications, the authors concluded.
Image Credit: Image by marian anbu juwan from Pixabay
View post:
How Far Are We from (Accurately and Safely) Editing Human Embryos? - Singularity Hub
- UC Irvine Study Reveals Risks Associated with Direct-to-Consumer Ads for Stem Cell and Exosome COVID-19 Therapies - India Education Diary - November 18th, 2023
- STEM | Description, Development, & Facts | Britannica - January 31st, 2023
- What is STEM Education? | Live Science - January 31st, 2023
- Science, Technology, Engineering, and Math, including Computer Science - ed - January 23rd, 2023
- What Does STEM Stand For? Definition, Degrees and More - January 23rd, 2023
- What Is STEM? - Definition & Resources for Teachers - January 23rd, 2023
- Science, technology, engineering, and mathematics - Wikipedia - January 23rd, 2023
- Stem Definition & Meaning - Merriam-Webster - January 23rd, 2023
- November: labblood-study | News and features - University of Bristol - November 7th, 2022
- Creative Medical Technology Holdings Announces FDA Clearance of Investigational New Drug (IND) Application for AlloStem, a Novel Cell Therapy for the... - November 7th, 2022
- Janssen to Highlight Latest Scientific Advances in Hematologic Diseases at ASH 2022 with Clinical and Real-World Data Across Innovative Pipeline and... - November 7th, 2022
- Type 2 Diabetes Stem Cell Therapy - Top U.S. Stem Cell ... - January 1st, 2022
- Cancer Drug Approvals from 2021 That Patients May Have Missed - Curetoday.com - January 1st, 2022
- Late effects in survivors of high-risk neuroblastoma following stem cell transplant with and without total body irradiation - DocWire News - January 1st, 2022
- The new life of a teenager with a strange tumor on his face after the operation - Market Research Telecast - January 1st, 2022
- Best of what was new in diabetes health for 2021 - Dickson Post - January 1st, 2022
- Hematopoietic Stem Cell Transplantation - StatPearls ... - December 22nd, 2021
- Autologous Stem Cell Transplant for Multiple Myeloma - December 22nd, 2021
- City of Hope presents leading-edge research on blood cancer therapies and its vaccine to reduce stem cell transplant complications at American Society... - December 22nd, 2021
- Adaptation Is Key to Advancing Care for Adult Patients With Leukemia - OncLive - December 22nd, 2021
- FDA Approves First Drug to Prevent Graft Versus Host Disease | FDA - FDA.gov - December 22nd, 2021
- Vera Therapeutics Announces Acquisition of Monoclonal Antibody From Pfizer to Treat BK Virus in Transplant Patients - Yahoo Finance - December 22nd, 2021
- After throwing goodbye party, woman with cancer finds hope close to home in Austin - Austin American-Statesman - December 22nd, 2021
- Dr. K.M. Cherian Heart Foundation & Educational Society Organized Cme Programme & Workshop On Cell Culture And Regenerative Medicine - APN... - December 22nd, 2021
- Namesake of new center a young man in love with the pursuit of knowledge - The Saint Anselm Crier - November 7th, 2021
- Red Cross blood drive focuses on sickle cell disease fight - Palladium-Item - November 7th, 2021
- Shockwave therapy brings new healing opportunities for heart attack patients and hope for people with spinal cord injuries - KULR-TV - November 7th, 2021
- 1st CRISPR Gene Editing Trial Slated to Open in Severe SCD Patients - Sickle Cell Anemia News - April 4th, 2021
- Transplant After CD19 CAR T-Cell Therapy Shows Durable Disease Control in Children, Young Adults With B-ALL - Cancer Network - April 4th, 2021
- Timely Bone Marrow Transplant by Fortis gives new lease of life to a patient with Multiple Myeloma - APN News - April 4th, 2021
- Kirron Kher is suffering with Multiple Myeloma: Know the causes, symptoms and more about this type of blood cancer - Jagran English - April 4th, 2021
- Decitabine Improved Outcomes for Patients With Refractory Prolonged Isolated Thrombocytopenia - Hematology Advisor - April 4th, 2021
- Lake in the Hills police officer and father of 4 kids battling rare cancer forced to retire - Lake and McHenry County Scanner - April 4th, 2021
- Insulin 100: How the road to a diabetes cure is yielding better treatments - News@UofT - April 4th, 2021
- Boxcar Scars Market |Exclusive Report on Latest Trends and Market Growth Opportunities - BioSpace - April 4th, 2021
- Merck Receives Positive EU CHMP Opinion for Updated Label of KEYTRUDA (pembrolizumab) To Include Results of Phase 3 KEYNOTE-361 Trial in Certain Adult... - April 4th, 2021
- BeyondSpring Announces Submission of New Drug Application to US FDA and China NMPA for Plinabulin and G-CSF Combination for the Prevention of... - April 4th, 2021
- Types of leukemia: Prevalence, treatment options, and prognosis - Medical News Today - February 14th, 2021
- Roche receives first FDA clearance for urine sample type for BK virus quantitative test to aid in the improvement of care for transplant patients -... - February 14th, 2021
- Energy drinks may damage the heart, researchers warnshould the FDA get involved? - Cardiovascular Business - February 14th, 2021
- FDA Approves G1 Therapeutics' COSELA (trilaciclib): The First and Only Myeloprotection Therapy to Decrease the Incidence of Chemotherapy-Induced... - February 14th, 2021
- Easter Ross mum of blood cancer tot urges would-be stem cell donors to show the love this Valentine's Day; Alness lass Adeline Davidson's plight... - February 14th, 2021
- Global Induced Pluripotent Market Positive Outlook, Revenue Generation & Leading Manufacturers, Forecast 2026||CELGENE CORPORATION; Astellas... - February 14th, 2021
- Leukemia in children: Symptoms, causes, treatment, outlook, and more - Medical News Today - February 7th, 2021
- After Bone Marrow Donation Saves 9-Year-Old Boy With Cancer, Boston Mom Fights To Raise Awareness - Here And Now - February 7th, 2021
- Understanding bone marrow transplant: The guidelines and the protocols - The New Indian Express - February 4th, 2021
- Why Cynata is hopeful its COVID treatment trial will succeed where others have failed - Business News Australia - February 4th, 2021
- Mobilize family caregivers to speed the rollout of Covid-19 vaccines - STAT - February 4th, 2021
- People With Cancer Should Receive COVID-19 Vaccine, Experts Say - Cancer Health Treatment News - February 4th, 2021
- Evotec and Medical Center Hamburg-Eppendorf Enter Partnership to Develop iPSC-Based Tissue Therapy f - PharmiWeb.com - February 4th, 2021
- APOE Tied to Increased Susceptibility to SARS-CoV-2 | ALZFORUM - Alzforum - February 4th, 2021
- Transforming Outcomes in Advanced CSCC with Immunotherapy - LWW Journals - February 4th, 2021
- Ashley Cain is living his worst nightmare as his baby daughter battles leukaemia in hospital - The Sun - February 4th, 2021
- Canada's blood supply has a diversity problem and people are dying because of it - CBC.ca - February 1st, 2021
- Autologous Stem Cell and Non Stem Based therapies Market Share, Size 2021 Global Industry Future Trends, Growth, Strategies,, Segmentation, In-depth... - February 1st, 2021
- Merck Receives Positive EU CHMP Opinion for Expanded Approval of KEYTRUDA (pembrolizumab) in Certain Patients With Relapsed or Refractory Classical... - February 1st, 2021
- Merck Presents Results From Head-to-Head Phase 3 KEYNOTE-598 Trial Evaluating KEYTRUDA (pembrolizumab) in Combination With Ipilimumab Versus KEYTRUDA... - February 1st, 2021
- Disabled People Are Waiting, Anxiously, For Lifesaving Covid-19 Vaccinations - Forbes - February 1st, 2021
- Family of Belfast woman Eimear Gooderham (25) share memories and dealing with grief in special UTV programme - Belfast Telegraph - February 1st, 2021
- Single-cell molecular profiling of all three components of the HPA axis reveals adrenal ABCB1 as a regulator of stress adaptation - Science Advances - February 1st, 2021
- The Need for New Biological Targets for Therapeutic Intervention in COPD - Pulmonology Advisor - February 1st, 2021
- What Patients With Cancer, Survivors Need to Know About the Emergency Use Authorization of COVID-19 Vaccine - Curetoday.com - December 19th, 2020
- Every Patient Treated With CRISPR Gene Therapy for Blood Diseases Continues to Thrive, More Than a Year On - Good News Network - December 19th, 2020
- Are Hiccups a Sign of the New Coronavirus? - Healthline - December 19th, 2020
- KEYTRUDA Plus LENVIMA Combination Demonstrated Statistically Significant Improvement in Overall Survival, Progression-Free Survival and Objective... - December 19th, 2020
- Covid-19 can have impact on heart too, say experts - Hindustan Times - December 19th, 2020
- Even if You've Had COVID-19 You Still Need the Vaccine - Healthline - December 19th, 2020
- The Link Between Cancer and Metabolic Dysfunction - Technology Networks - December 19th, 2020
- Diamyd Medical and Critical Path Institute announce data sharing collaboration to develop advanced drug development tools in type 1 diabetes -... - December 19th, 2020
- Gene therapy gives man with sickle cell disease the chance for a better future - Science Codex - December 3rd, 2020
- Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate Safety and Therapeutic Efficacy of Angiogenesis Induced by Intraarterial Autologous... - December 3rd, 2020
- Coronavirus Updates: The Latest Treatments and Vaccines - GovTech - December 3rd, 2020
- Graft Versus Host Disease (GVHD) Patient Population, Treatment Algorithm, Medical Practices And Epidemiology Forecast To 2030 - The Market Feed - December 3rd, 2020
- Government of Canada and JDRF Canada announce new research funding to accelerate stem cell-based therapies for type 1 diabetes - India Education Diary - December 3rd, 2020
- Coinfection: more than the sum of its parts - Science Codex - November 19th, 2020
- Angiocrine Bioscience Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to AB-205 (Universal E-CEL Cell Therapy) to... - November 17th, 2020
- FDA Approves Merck's KEYTRUDA in Combination With Chemotherapy for Patients With Locally Recurrent Unresectable or Metastatic Triple?Negative Breast... - November 17th, 2020
- Human mesenchymal stromal cells do not express ACE2 and TMPRSS2 and are not permissive to SARS-CoV-2 infection - DocWire News - November 17th, 2020
- Cleveland Clinic team draws a link between COVID-19 protection and the sleep aid melatonin - FierceBiotech - November 17th, 2020
- UH announces participation in clinical trial testing antibodies to treat COVID-19 in adults - News 5 Cleveland - November 7th, 2020